Lovastatin-d9

• Description:

  Lovastatin-d9 is the deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

• Product Name Alternative:

  Mevinolin-d9

• UNSPSC:

  12352005

• Target:

  Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR) ; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis; Autophagy; Metabolic Enzyme/Protease; Others

• Field of Research:

  Cardiovascular Disease; Cancer

• Purity:

  99.04

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(O[C@H]1C[C@H](C=C2C=C[C@H](C)[C@@H]([C@]21[H])CC[C@H]3OC(C[C@@H](C3)O)=O)C)C(C([2H])([2H])[2H])([2H])C([2H])([2H])C([2H])([2H])[2H]

• Molecular Formula:

  C24H27D9O5

• Molecular Weight:

  413.60

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62 (15) :10J-15J.|[3]Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28 (3) :1077-83.|[4]Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73 (2) :437-48.|[5]Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2 (7) :517-26.|[6]Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60 (1) :45-55.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported